As of 30 Sep 2025, 29 institutional investors reported holding $272,401,354 in principal (par value) of TRAVERE THERAPEUTICS INC - NOTE 2.250% 3/0.
| Period | Principal | Value | Change | Price (% of par) (Median) | Investors |
|---|---|---|---|---|---|
| 2025 Q4 | $0 | $0 | -$11,528 | 0 | |
| 2025 Q3 | $272,401,354 | $307,917,277 | +$569,601 | 112.88% | 29 |
| 2025 Q2 | $279,664,978 | $303,344,890 | +$1,782,692 | 95.39% | 26 |
| 2025 Q1 | $277,011,293 | $276,983,110 | +$13,929,020 | 99.8% | 28 |
| 2024 Q4 | $264,062,863 | $250,352,690 | +$9,069,609 | 95.24% | 21 |
| 2024 Q3 | $257,683,037 | $224,077,029 | +$11,645,577 | 86.4% | 25 |
| 2024 Q2 | $253,865,742 | $203,588,240 | -$12,098,839 | 64.79% | 18 |
| 2024 Q1 | $273,167,017 | $213,304,940 | -$34,119,308,890 | 63.47% | 18 |
| 2023 Q4 | $334,700,000 | $220,380,890 | +$27,118,701 | 66.0% | 20 |
| 2023 Q3 | $293,624,167 | $216,434,339 | +$1,578,777 | 64.72% | 22 |
| 2023 Q2 | $302,112,167 | $244,546,345 | -$10,623,621 | 81.08% | 21 |
| 2023 Q1 | $312,983,167 | $325,418,603 | +$10,031,881 | 98.3% | 21 |
| 2022 Q4 | $301,166,967 | $274,825,761 | -$26,924,802 | 91.19% | 21 |
| 2022 Q3 | $282,429,300 | $289,316,637 | -$825,518 | 102.07% | 23 |
| 2022 Q2 | $239,416,100 | $244,284,801 | -$22,593,875 | 100.32% | 21 |
| 2022 Q1 | $257,273,349 | $279,703,965 | +$279,703,965 | 106.45% | 23 |